AXGN's 2025 revenue guidance includes price growth aligned with CPI, with the remainder driven by volume and mix.
The company is confident in the benefit-risk proposition of its breast resensation technique but acknowledges the need for additional studies over the next three to five years to support broader adoption.
AXGN's Advanced Processing Center (APC) has three times the previous capacity, and the company is confident in meeting capacity needs during the current planning period.
The reported share count is expected to remain stable, with no plans for a capital raise in the near term.
AXGN plans to provide further updates on its progress and future plans at its March Investor Day and the next earnings call.